MRI differentiation of cardiomyopathy showing left ventricular hypertrophy and heart failure: Differentiation between cardiac amyloidosis, hypertrophic cardiomyopathy, and hypertensive heart disease

Japanese Journal of Radiology

Volumn 31, Issue 10, 2013, Pages 693-700

  Takeda, Minako ^a   Amano, Yasuo ^a   Tachi, Masaki ^a   Tani, Hitomi ^a   Mizuno, Kyoichi ^a   Kumita, Shinichiro ^a  

^a NIPPON MEDICAL SCHOOL   (Japan)

Author keywords

Cardiac amyloidosis; Hypertensive heart disease; Hypertrophic cardiomyopathy; Late gadolinium enhancement; Magnetic resonance imaging

Indexed keywords

ADULT; AGED; ARTICLE; CARDIAC IMAGING; CARDIOMYOPATHY; CARDIOVASCULAR MAGNETIC RESONANCE; CLINICAL ARTICLE; FEMALE; HEART AMYLOIDOSIS; HEART DISEASE; HEART EJECTION FRACTION; HEART FAILURE; HEART FUNCTION; HEART LEFT VENTRICLE EJECTION FRACTION; HEART LEFT VENTRICLE ENDDIASTOLIC VOLUME; HEART LEFT VENTRICLE HYPERTROPHY; HUMAN; HYPERTENSION; HYPERTENSIVE HEART DISEASE; HYPERTROPHIC CARDIOMYOPATHY; IMAGE ANALYSIS; MALE; NONISCHEMIC CARDIOMYOPATHY; PERICARDIAL EFFUSION; PLEURA EFFUSION; PRIORITY JOURNAL; VECTORCARDIOGRAPHY;

AGED; AGED, 80 AND OVER; AMYLOIDOSIS; BIOPSY; CARDIOMYOPATHY, HYPERTROPHIC; CONTRAST MEDIA; DIAGNOSIS, DIFFERENTIAL; FEMALE; GADOLINIUM DTPA; HEART DISEASES; HEART FAILURE; HUMANS; HYPERTENSION; HYPERTROPHY, LEFT VENTRICULAR; IMAGE INTERPRETATION, COMPUTER-ASSISTED; MAGNETIC RESONANCE IMAGING; MALE; MIDDLE AGED;

EID: 84886438080     PISSN: 18671071     EISSN: 1867108X     Source Type: Journal    
DOI: 10.1007/s11604-013-0238-0     Document Type: Article

References (29)

1. Levy D, Garrison RJ, Savage DD, Kannel WB, Castelli WP. Prognostic implications of echocardiographically determined left ventricular mass in the Framingham Heart Study. N Engl J Med. 1990;322:1561-6. (Pubitemid 20176696)
2. Perugini E, Rapezzi C, Piva T, Leone O, Bacchi L, Riva L, et al. Non-invasive evaluation of cardiac amyloidosis by gadolinium cardiac magnetic resonance. Heart. 2006;92:343-9.
3. Falk RH. Cardiac amyloidosis: a treatable disease, often overlooked. Circulation. 2011;124:1079-85.
4. Elliott P, McKenna WJ. Hypertrophic cardiomyopathy. Lancet. 2004;363:1881-91. (Pubitemid 38748646)
5. Harris KM, Sipirito P, Maron MS, Zenovich AG, Formisano F, Lesser JR, et al. Prevalence, clinical profile, and significance of left ventricular remodeling in the end-stage phase of hypertrophic cardiomyopathy. Circulation. 2006;114:216-25. (Pubitemid 44297115)
6. Drazner MH. The progression of hypertensive heart disease. Circulation. 2011;123:327-34.
7. James MA, Saadeh AM, Jones JV. Wall stress and hypertension. J Cardiovasc Risk. 2000;3:187-90. (Pubitemid 30463747)
8. Rudolph A, Abdel-Aty H, Bohl S, Boye P, Zagrosek A, Dietz R, et al. Noninvasive detection of fibrosis applying contrast-enhanced cardiac magnetic resonance in different forms of left ventricular hypertrophy. J Am Coll Cardiol. 2009;53:284-91.
9. Sipola P, Magga J, Husso M, Jaaskelainen P, Peuhkurinen K, Kuusisto J. Cardiac MRI assessed left ventricular hypertrophy in differentiating hypertensive heart disease from hypertrophic cardiomyopathy attributable to a sarcomeric gene mutation. Eur Radiol. 2011;7:1383-9.
10. Puntmann VO, Jahnke C, Gebker R, Schnackenburg B, Fox KF, Fleck E, et al. Usefulness of magnetic resonance imaging to distinguish hypertensive and hypertrophic cardiomyopathy. Am J Cardiol. 2010;106:1016-22.
11. Maceria AM, Joshi J, Prasad SK, Moon JC, Perugini E, Harding I, et al. Cardiovascular magnetic resonance in cardiac amyloidosis. Circulation. 2005;111:186-93. (Pubitemid 40139730)
12. Alfakih K, Plein S, Thiele H, Jones T, Ridgway JP, Sivananthan MU. Normal human left and right ventricular dimensions for MRI as assessed by turbo gradient echo and steady-state free precession imaging sequences. J Magn Reson Imaging. 2003;17:323-9. (Pubitemid 36259246)
13. Maron MS. Clinical utility of cardiovascular magnetic resonance in hypertrophic cardiomyopathy. J Cardiovasc Magn Reson. 2012;14:13.
14. Efthimiadis GK, Giannakoulas G, Parharidou DG, Karvounis HI, Mochlas ST, Styliadis H, et al. Prevalence of systolic impairment in an unselected regional population with hypertrophic cardiomyopathy. Am J Cardiol. 2006;98:1272-96. (Pubitemid 44584119)
15. Mancia G, De Backer G, Dominiczak A, Cifkova R, Fagard R, Germano G, et al. 2007 ESH-ESC Practice guidelines for the management of arterial hypertension: ESH-ESC task force on the management of arterial hypertension. J Hypertens. 2007;25:1751-62. (Pubitemid 47356612)
16. Cerqueira MD, Weissman NJ, Dilsizian V, Jacobs AK, Kaul S, Laskey WK, et al. Standardized myocardial segmentation and nomenclature for tomographic imaging of the heart. A statement for healthcare professionals from the Cardiac Imaging Committee of the Council on Clinical Cardiology of the American Heart Association. Circulation. 2002;105:539-42. (Pubitemid 34262671)
17. Mahrholdt H, Wagner A, Judd RM, Sechtem U, Kim RJ. Delayed enhancement cardiovascular magnetic resonance assessment of non-ischaemic cardiomyopathies. Eur Heart J. 2005;26:1461-74. (Pubitemid 41373486)
18. Kim RJ, Wu E, Rafael A, Chen EL, Parker MA, Simonetti O, et al. The use of contrast-enhanced magnetic resonance imaging to identify reversible myocardial dysfunction. N Engl J Med. 2000;343:1445-53.
19. Hosch W, Kristen AV, Libicher M, Dengler TJ, Aulumann S, Heye T, et al. Late enhancement in cardiac amyloidosis: correlation of MRI enhancement pattern with histopathological findings. Amyloid. 2008;3:196-204.
20. Maron MS, Appelbaum E, Harrigan CJ, Buros J, Gibson CM, Hanna C, et al. Clinical profile and significance of delayed enhancement in hypertrophic cardiomyopathy. Circ Heart Fail. 2008;1:184-91.
21. Querejeta R, Varo N, Lopez B, Larman M, Artiñano E, Etayo JC, et al. Serum carboxy-terminal propeptide of procollagen type I is a marker of myocardial fibrosis in hypertensive heart disease. Circulation. 2000;101:1729-35. (Pubitemid 30196635)
22. Anderson K, Hennersdorf M, Cohnen M, Blondin D, Modder U, Poll LW. Myocardial delayed contrast enhancement in patients with arterial hypertension: initial results of cardiac MRI. Eur J Radiol. 2009;71:75-81.
23. Fattiri R, Rocchi G, Celletti F, Bertaccini P, Rapezzi C, Gavelli G. Contribution of magnetic resonance imaging in the differential diagnosis of cardiac amyloidosis and symmetric hypertrophic cardiomyopathy. Am Heart J. 1998;136:824-30. (Pubitemid 28506882)
24. Maron MS, Hauser TH, Dubrow E, Horst TA, Kissinger KV, et al. Right ventricular involvement in hypertrophic cardiomyopathy. Am J Cardiol. 2007;100:1293-8. (Pubitemid 47500158)
25. Cacoub P, Axler O, Dezuttere D, Hausfater P, Amoura Z, Watter S, et al. Amyloidosis and cardiac involvement. Ann Med Interne (Paris). 2000;151:611-7. (Pubitemid 32109349)
26. Berk JL. Pleural effusions in systemic amyloidosis. Curr Opin Pulm Med. 2005;11:324-8. (Pubitemid 41073157)
27. Biagini E, Coccolo F, Ferlito M, Perugini E, Rocchi G, Bacchi-Reggiani L, et al. Dilated-hypokinetic evolution of hypertrophic cardiomyopathy: prevalence, incidence, risk factors, and prognostic implications in pediatric and adult patients. J Am Coll Cardiol. 2005;46:1543-50. (Pubitemid 41446193)
28. Hosch W, Bock M, Libicher M, Ley S, Hegenbart U, Dengler TJ, et al. MR-relaxometry of myocardial tissue: significant elevation of T1 and T2 relaxation times in cardiac amyloidosis. Invest Radiology. 2007;42:636-42. (Pubitemid 47262932)
29. Kono AK, Yamada N, Higashi M, Kanzaki S, Hashimura H, Morita Y, et al. Dynamic late gadolinium enhancement simply quantified using myocardium to lumen signal ratio: normal range of ratio and diffuse abnormal enhancement of cardiac amyloidosis. J Magn Reson Imaging. 2011;34:50-5.